1.Schwartz, B, Bell, D, Hughes, JM. Preventing the emergence of antimicrobial resistance: a call for action by clinicians, public health officials, and patients. JAMA 1997;278:944–945.
2.McGowan, JE, Tenover, FC. Control of antimicrobial resistance in the health care system. Infect Dis Clin North Am 1997;11:297–311.
3.Tenover, FC, Tokars, J, Swenson, J, Paul, S, Spitalny, K, Jarvis, WR. Ability of clinical laboratories to detect antimicrobial agent-resistant enterococci. J Clin Microbiol 1993;31:1695–1699.
4.Tenover, FC, Lancaster, MV, Hill, BC, et al.Characterization of staphylococci with reduced susceptibilities to vancomycin and other gly-copeptides. J Clin Microbiol 1998;36:1020–1027.
5.Tenover, FC, Swenson, JM, O'Hara, CM, Stocker, SA. Ability of commercial and reference antimicrobial susceptibility testing methods to detect vancomycin resistance in enterococci. J Clin Microbiol 1995;33:1524–1527.
6.Tenover, FC, Mohammed, MJ, Stelling, J, O'Brien, T, Williams, R. Ability of laboratories to detect emerging antimicrobial resistance: proficiency testing and quality control results from the World Health Organization's external quality assurance system for antimicrobial susceptibility testing. J Clin Microbiol 2001;39:241–250.
7.Centers for Disease Control and Prevention. National Nosocomial Infections Surveillance (NNIS) System report: data summary from January 1992-April 2000, issued June 2000. Am J Infect Control 2000;28:429–448.
8.Fridkin, SK. Increasing prevalence of antimicrobial resistance in intensive care units. Crit Care Med 2001;29:N64–N68.
9.Centers for Disease Control and Prevention. Laboratory capacity to detect antimicrobial resistance, 1998. MMWR 2001;48:1167–1171.
10.Tenover, FC, Mohammed, MJ, Gorton, TS, Dembek, ZF. Detection and reporting of organisms producing extended-spectrum beta-lacta-mases: survey of laboratories in Connecticut. J Clin Microbiol 1999;37:4065–4070.
11.Steward, CD, Wallace, D, Hubert, SK, et al.Ability of laboratories to detect emerging antimicrobial resistance in nosocomial pathogens: a survey of Project ICARE laboratories. Diagn Microbiol Infed Dis 2000;38:59–67
12.Deikema, DJ, Pfaller, MASmayevsky, J, et al.Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific Region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001;32:S114–S132.
13.Sahm, DF, Marsilio, MK, Piazza, G. Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with the Surveillance Network Database-USA Clin Infect Dis 1999;29:259–263.
14.Edmond, MB, Wallace, SE, McClish, DK, Pfaller, MA, Jones, RN, Wenzel, RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999;29:239–244.
15.Swenson, JM, Clark, NC, Sahm, DF, et al.Molecular characterization and multilaboratory evaluation of Enterococcus faecalis ATCC 51299 for quality control of screening tests for vancomycin and high-level aminoglycoside resistance in enterococci. J Clin Microbiol 1995;33:3019–3021.
16.Rosenberg, J, Tenover, FC, Wong, J, Jarvis, W, Vugia, DJ. Are clinical laboratories in California accurately reporting vancomycin-resistant enterococci? J Clin Microbiol 1997;35:2526–2530.
17.Yigit, H, Steward, CD, Biddle, JW, Tenover, FC. Characterization of β-lac-tamases and porin changes in carbapenem-resistant isolates of Klebsiella pneumoniae and Serratia marcescens. Presented at the 99th General Meeting of the American Society for Microbiology; May 30-June 3, 1999; Washington, DC. Abstract A-61.
18.Garrett, DO, Jochimsen, E, Murfitt, K, et al.The emergence of decreased susceptibility to vancomycin in Staphylococcus epidermidis. Infect Control Hosp Epidemiol 1999;20:167–170.
19.Rasheed, JK, Tenover, FC, Anderson, GJ, et al.Characterization of extended-spectrum beta-lactamase reference strain, Klebsiella pneumoniae K6 (ATCC 700603), which produces the novel enzyme SHV-18. Antimicrob Agents Chemother 2000;44:2382–2388.
20.National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, 4th ed. Wayne, PANational Committee for Clinical Laboratory Standards; 1997. Approved standard M7-A4.
21.National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility Tests, 6th ed. Wayne, PA: National Committee for Clinical Laboratory Standards; 1997. Approved standard M2-A6.
22.National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing. Wayne, PA: National Committee for Clinical Laboratory Standards; 1999. Approved standard M100-S9.
23.Richards, C, Emori, TG, Edwards, J, et al.Characteristics of hospitals and infection control professionals participating in the National Nosocomial Infections Surveillance System 1999. Am J Infect Control 2001;29:400–403.
24.Jones, RN. Method preferences and test accuracy of antimicrobial susceptibility testing. Arch Pathol Lab Med 2001;125:1285–1289.
25.Smith, TL, Pearson, ML, Wilcox, KR, et al.Emergence of vancomycin resistance in Staphylococcus aureus: Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med 1999;340:493–501.
26.Centers for Disease Control and Prevention. Staphylococcus aureus with reduced susceptibility to vancomycin: Illinois, 1999. MMWR 2000;48:1165–1167.
27.Hageman, JC, Pegues, DAJepson, C, et al.Vancomycin-intermediate Staphylococcus aureus in a home healthcare patient. Emerg Infect Dis 2001;7:1023–1025.
28.Fridkin, SKVancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious diseases specialist needs to know. Clin Infect Dis 2001;32:108–115.
29.Centers for Disease Control and Prevention. Interim guidelines for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin. MMWR 1997;46:626-628, 635.
30.Tenover, FC, Biddle, JW, Lancaster, MV. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 2001;7:327–332.
31.Marlowe, EM, Cohen, MD, Hindler, JF, Ward, KW, Bruckner, DAPractical strategies for detecting and confirming vancomycin-intermediate Staphylococcus aureus: a tertiary-care hospital laboratory's experience. J Clin Microbiol 2001;39:2637–2639.
32.Fridkin, SK, Gaynes, RP. Antimicrobial resistance in intensive care units. Clin Chest Med 1999;20:303–316.
33.Grist, R. External factors affecting imipenem performance in dried microdilution MIC plates. J Clin Microbiol 1992;30:535–536.
34.White, RL, Kays, MB, Friedrich, LV, Brown, EW, Koonce, JR. Pseudoresistance of Pseudomonas aeruginosa resulting from degradation of imipenem in an automated susceptibility testing system with predried panels. J Clin Microbiol 1991;29:398–400.
35.Carmeli, Y, Eichelberger, K, Soja, D, et al.Failure of quality control measures to prevent reporting of false resistance to imipenem, resulting in a pseudo-outbreak of imipenem-resistant Pseudomonas aeruginosa. J Clin Microbiol 1998;36:595–597.
36.National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing. Wayne, PA: National Committee for Clinical Laboratory Standards; 1998. Approved standard M100-S8.